The global psychiatric digital biomarkers market was estimated at USD 521.9 million in 2023 and is projected to grow at a CAGR of 23.9% from 2024 to 2030. The increasing prevalence of mental health disorders, advancements in digital health technologies and growing demand for personalized medicine drive the market. Rising adoption of wearable devices and mobile health apps in mental healthcare contribute to the market growth. In April 2024, Sensors published a review on digital phenotyping's impact on neurological diseases, showing its potential to refine clinical trials and aid in early detection and monitoring through telemedicine and sensor technologies.
The global burden of mental health disorders is on the rise, with conditions such as depression, anxiety, bipolar disorder, and schizophrenia affecting millions of people worldwide. In 2023, Mental Health America, Inc. found that 20.17% of youths aged 12-17 had encountered a major depressive episode, with 15% suffering severe impairment affecting daily activities. This increasing prevalence is driving the need for more effective tools to monitor and manage mental health conditions, leading to a growing interest in psychiatric digital biomarkers. In July 2022, Pervasive and Mobile Computing published findings showing significant differences in mood and digital markers (such as sleep and phone usage) between depressed and non-depressed individuals. It also confirmed that depression status could be accurately predicted using these digital biomarkers alone or combined with mood ratings.
Technological advancements in digital health technologies revolutionize the field of mental healthcare. Innovations such as artificial intelligence (AI), machine learning, and data analytics enable the development of sophisticated digital biomarkers that provide valuable insights into an individual's mental health status. AI-powered algorithms analyze data from smartphone sensors to detect changes in behavior patterns that indicate early signs of a mental health crisis.
In November 2023, an article in Frontiers in Psychiatry highlighted the potential of digital biomarkers in predicting and managing mood disorders, noting how smartphone data can monitor depression and treatment responses, wearable devices can track mood disorders more accurately in real-world settings, and AI advancements are opening up new diagnostic and therapeutic avenues.
There is a growing demand for personalized medicine in mental healthcare, as healthcare providers seek to tailor treatment plans to individual patients' needs. Psychiatric digital biomarkers play a crucial role in enabling personalized interventions by providing objective data on patients' symptoms and treatment responses. The increasing adoption of wearable devices and mobile health apps further fuels this trend, allowing for continuous monitoring of patients outside traditional clinical settings. In March 2022, DTU Health Tech researchers developed a method using voice analysis to identify bipolar disorder in individuals and monitor mood changes in patients, with personalized models providing the most accurate results.
This product will be delivered within 1-3 business days.
The global burden of mental health disorders is on the rise, with conditions such as depression, anxiety, bipolar disorder, and schizophrenia affecting millions of people worldwide. In 2023, Mental Health America, Inc. found that 20.17% of youths aged 12-17 had encountered a major depressive episode, with 15% suffering severe impairment affecting daily activities. This increasing prevalence is driving the need for more effective tools to monitor and manage mental health conditions, leading to a growing interest in psychiatric digital biomarkers. In July 2022, Pervasive and Mobile Computing published findings showing significant differences in mood and digital markers (such as sleep and phone usage) between depressed and non-depressed individuals. It also confirmed that depression status could be accurately predicted using these digital biomarkers alone or combined with mood ratings.
Technological advancements in digital health technologies revolutionize the field of mental healthcare. Innovations such as artificial intelligence (AI), machine learning, and data analytics enable the development of sophisticated digital biomarkers that provide valuable insights into an individual's mental health status. AI-powered algorithms analyze data from smartphone sensors to detect changes in behavior patterns that indicate early signs of a mental health crisis.
In November 2023, an article in Frontiers in Psychiatry highlighted the potential of digital biomarkers in predicting and managing mood disorders, noting how smartphone data can monitor depression and treatment responses, wearable devices can track mood disorders more accurately in real-world settings, and AI advancements are opening up new diagnostic and therapeutic avenues.
There is a growing demand for personalized medicine in mental healthcare, as healthcare providers seek to tailor treatment plans to individual patients' needs. Psychiatric digital biomarkers play a crucial role in enabling personalized interventions by providing objective data on patients' symptoms and treatment responses. The increasing adoption of wearable devices and mobile health apps further fuels this trend, allowing for continuous monitoring of patients outside traditional clinical settings. In March 2022, DTU Health Tech researchers developed a method using voice analysis to identify bipolar disorder in individuals and monitor mood changes in patients, with personalized models providing the most accurate results.
Global Psychiatric Digital Biomarkers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the publisher has segmented the global psychiatric digital biomarkers market report based on type, clinical practice, end use, and region.- Type Outlook (Revenue, USD Million, 2018 - 2030)
- Wearable
- Mobile based Applications
- Sensors
- Others
- Clinical Practice Outlook (Revenue, USD Million, 2018 - 2030)
- Diagnostic Psychiatric Digital Biomarkers
- Monitoring Psychiatric Digital Biomarkers
- Predictive and Prognostic Psychiatric Digital Biomarkers
- Other's (Safety, Pharmacodynamics/ Response, Susceptibility)
- End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Healthcare companies
- Healthcare Providers
- Payers
- Others (Patient, caregivers)
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Psychiatric Digital Biomarkers Market Variables, Trends & Scope
Chapter 4. Psychiatric Digital Biomarkers Market: Type Estimates & Trend Analysis
Chapter 5. Psychiatric Digital Biomarkers Market: Clinical Practice Estimates & Trend Analysis
Chapter 6. Psychiatric Digital Biomarkers Market: End Use Estimates & Trend Analysis
Chapter 7. Psychiatric Digital Biomarkers Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Koneksa
- Biogen Inc.
- Empatica Inc.
- Vivo Sense
- IXICO plc
- Huma
- Sonde Health, Inc.
- Clario
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 521.9 Million |
| Forecasted Market Value ( USD | $ 2290 Million |
| Compound Annual Growth Rate | 23.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
